DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20175677

Comparative study of effects of ramosetron and ondansetron on global satisfaction of patients on cisplatin chemotherapy in head and neck cancers

Swapnil Srivastava, Quazi Shahir Ahmed, Kauser Sayedda

Abstract


Background: To compare level of satisfaction of the patients receiving ramosetron and ondansetron in prevention of acute and delayed nausea and vomiting associated with cisplatin chemotherapy.

Methods: 60 patients were recruited in the study. Patients were randomly allocated to ramosetron (R) and ondansetron group (O). Patients were screened between day 1 and day 7. Study visits included clinic visits on day 8, day 9 and day 14. Patient diaries were used to record patients’ global satisfaction which was based on severity of nausea and vomiting using visual analogue scale (VAS), recorded daily until day 12 starting from day 8. On 14th day the patient diary cards were collected back.

Results: VAS score was significantly lower in R group (46.2±4.95) as compared to O group (63.7±5.06) (p<0.01) in acute phase of nausea and vomiting indicating level of satisfaction higher in R group. Similarly, in delayed and overall phase R group (49.57±14.63 and 48.9±12.91 respectively) experienced lower range of scoring on VAS scale as compared to O group (63.0±8.49 and 63.10±7.38 respectively). The difference was statistically significant (p<0.01).

Conclusions: Level of overall satisfaction of the patients in R group was significantly higher as compared to O group in patients receiving the two drugs for prevention of nausea and vomiting caused by cisplatin chemotherapy in head and neck cancer patients.


Keywords


Cisplatin, Level of satisfaction, Ondansetron, Ramosetron, VAS

Full Text:

PDF

References


Schnell FM. Chemotherapy induced nausea and vomiting: the importance of acute antiemetic control. Oncol. 2002;8:187-98.

Coates A, Abraham S, Kaye SB. On the receiving end; patients’ perceptions of the side-effects of cancer chemotherapy. Eur J Clin Oncol. 1983;19:203.

Grunberg SM, Densen RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-3.

Daum BB, Deuson RR, Mavros P, Hansen M, Herrestedt J. Delayed Nausea and Vomiting Continue to Reduce Patient’s Quality of Life after Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment. J Clin Oncol. 2006;24:4472-8.

Andrews PLR, Davis CJ, Bighanis DH, Honvthoin J, Mashell L. The abdominal visceral innervation and the emetic reflex, pathway and plasticity. Can J Physiol Pharmacol. 1990:68:325-45.

Habib AS, Gan TJ. Evidence based management of post-operative nausea and vomiting: A review. Can J Anesth. 2004;51:326-41.

Berger M, Gray JA, Roth BL Gray R. The expanded biology of serotonin. Ann Rev Med. 2009;60:355-66.

Jones AW, Helander A. Time course and reproducibility of urinary excretion profiles of ethanol, methanol, and the ratio of serotonin metabolites after intravenous infusion of ethanol. Alcohol Clin Exp Res. 1999;23(12):1921-6.

Janelsins MC, Tejani M, Kamen C, Peoples A, Mustian KM, Morrow GR. Current Pharmacotherapy for Chemotherapy-Induced Nausea and Vomiting in Cancer Patients. Exp Opinion Pharmacotherap. 2013;14(6):757-66.

Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today. 2002;38:75-89.

Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacol. 2007;15(1):5-9.

Cheirsilpa A, Sinthusake T, Songsakkaesorn A, Viswaprasit S, Chulaka K, Changkuingdee N. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin based chemotherapy: A randomized trial. Jpn J Clin Oncol. 2005;35:695-9.

Kim MS, Kim DW, Woo SH, Yon JH, Lee S. Effect of ramosetron on shivering during spinal anaesthesia. Korean J Anesthesiol. 2010;58:256-9.

Roy BG, Daniel HK, CorneVL, Rene V. The validation of visual analogue scale for patient satisfaction after total hip arthroplasty. Eur Ortho Traumatol. 2012;75(2):1402-7.

Tomas C, Pedro AC, Carmen P, Ricardo A, Cesar A, Ali AB et al. Clinical management, expectations and satisfaction of patients with moderate to severe allergic rhino-conjunctivitis treated with SQ standardized grass allergen tablet under routine clinical practice conditions in Spain. Clin Mol Allerg. 2017;15(1):361-7.

Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events(CTCAE) v3.0 is the New Standard for Oncology clinical trials. J Clin Oncol. 2004;22:6098.

Percie DS, Rudd JA, Adfel CC, Andrews PLR. Cisplatin induced emesis: Systematic review and metaanalysis of the ferret model and the effects of 5HT3 receptor antagonists. Cancer Chemo Pharmacol. 2011;67(3):667-86.

Akuzawa S, Ito H, Yamaguchi T. Comparative study of [3H] ramosetron and [3H] granisetron binding in the cloned human 5-hydroxytryptamine3 receptors. Jpn J Pharmacol. 1998;78:381-4.

Sanmukhani JJ, Pawar P, Mittal R. Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience. South Asian J Cancer. 2014;3(2):132-7.

Park SK, Cho EJ, Kang SH, Lee YJ, Kim DA. A randomized, double-blind study to evaluate the efficacy of ramosetron and palonosetron for prevention of postoperative nausea and vomiting after gynecological laparoscopic surgery. Korean J Anaesthesiol. 2013;64(2):133-7.

Piya P, Mungkorn T, Chaivet R, Adisai C. Comparison of Ramosetron with Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control trial. J Arthroplasty. 2017;32(3):1040-3.

Shi Y, He X, Yang S, Ai B, Zhang C, Huang T et al. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemo. 2007;53:44-50.